Gilead Sciences announced positive data regarding Livdelzi for PBC and bulevirtide for chronic HDV, underscoring progress in liver disease treatment. During the last quarter, the company also reported Q1 financial results, announced positive outcomes for Trodelvy in cancer treatment, and shared updates on strategic partnerships, all highlighting its ongoing innovation. Despite these developments, Gilead's share price saw a minor 1.78% decline, in line with a flat market movement, suggesting that these events neither significantly added to nor detracted from the broader trend in the market. We've identified 2 warning signs for Gilead Sciences that you should be aware of.NasdaqGS:GILD Revenue & Expenses Breakdown as at May 2025 The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. The recent announcements from Gilead Sciences regarding positive data on Livdelzi and bulevirtide could bolster investor sentiment, aligning with the company’s broader narrative of expanding its presence in liver disease treatments. These advancements are poised to enhance revenue and earnings forecasts, particularly as Gilead aims to capture larger markets with its innovative therapies, like lenacapavir for PrEP and Trodelvy in oncology. However, the minor 1.78% decline in share price, despite these significant developments, suggests that the market may have already priced in the potential impact, or that broader market trends have neutralized the effect of these announcements. Over the three-year period ending April 2025, Gilead's total shareholder return reached 78.08%, presenting a stark contrast to more recent subdued price movements. Despite these longer-term gains outperforming the US Biotechs industry’s one-year decline of 14.1%, Gilead's earnings growth is forecast to continue pacing slower than the US market, which could influence investor expectations. Currently, the share price trading at a discount to the US$115.02 consensus price target indicates the potential for upside, contingent upon the realization of anticipated revenue and earnings growth. According our valuation report, there's an indication that Gilead Sciences' share price might be on the cheaper side. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Story Continues Companies discussed in this article include NasdaqGS:GILD. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]
Gilead Sciences (NasdaqGS:GILD) Presents Promising Data On Livdelzi And Bulevirtide At EASL 2025
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...